Table 3.
Univariable and multivariable analyses for RFS and OS in HR+ and HR– breast cancer patients
| Variable | Univariable RFS HR (95% CI) |
p | Multivariable RFS HR (95% CI) |
p | Univariable OS HR(95% CI) |
p | Multivariable OS HR (95% CI) |
p |
|---|---|---|---|---|---|---|---|---|
| Hormone receptor-positive | ||||||||
| Postmenopausal vs Premenopausal | 1.2 [0.68–2.13] | 0.525 | 1.48 [0.69–3.19] | 0.318 | ||||
| cN: N + vs N0 | 3.17 [1.42–7.09] | 0.005 | 2.37 [0.88–6.4] | 0.089 | 13.62 [1.85–100.55] | 0.01 | 4.89 [0.58–40.88] | 0.144 |
| cAJCC | < 0.001 | 0.003 | < 0.001 | < 0.001 | ||||
| II vs I | 1.07 [0.13–9.05] | 0.65 [0.06–6.93] | 14.55 [4.96–42.71] | 10.48 [3.38–32.53] | ||||
| III vs I | 4.73 [0.54–41.02] | 2.56 [0.22–30.45] | ||||||
| SBR | 1.5 [0.82–2.77] | 0.193 | 1.24 [0.67–2.31] | 0.497 | 2.11 [0.97–4.61] | 0.061 | 1.76 [0.77–3.99] | 0.179 |
| 2 vs 1 | ||||||||
| 3 vs 1 | ||||||||
| pAJCC | 0.035 | Not includeda | 0.152 | Not includeda | ||||
| I vs 0 | 0.42 [0.08–2.19] | 0.51 [0.05–4.95] | ||||||
| II vs 0 | 0.83 [0.19–3.56] | 0.81 [0.10–6.34] | ||||||
| III vs 0 | 1.56 [0.37–6.68] | 1.72 [0.22–13.28] | ||||||
| pCR: Yes vs No | 1.08 [0.26–4.45] | 0.919 | 3.37 [0.69–16.45] | 0.133 | 1 [0.14–7.45] | 0.996 | 3.46 [0.41–29.31] | 0.255 |
| HER2 low vs 0 | 1.22 [0.66–2.27] | 0.519 | 1.52 [0.8–2.89] | 0.207 | 0.8 [0.37–1.73] | 0.577 | 1.21 [0.54–2.73] | 0.649 |
| Hormone receptor-negative | ||||||||
| Postmenopausal vs Premenopausal | 2.08 [1.14–3.81] | 0.017 | 1.8 [0.91–3.56] | 0.092 | 3.21 [1.49–6.94] | 0.003 | 3.09 [1.24–7.67] | 0.015 |
| N: N + vs N0 | 2.48 [1.28–4.79] | 0.007 | 1.37 [0.58–3.27] | 0.473 | 3.45 [1.31–9.08] | 0.012 | 1.72 [0.47–6.27] | 0.524 |
| cAJCC | < 0.001 | 0.099 | < 0.001 | 0.552 | ||||
| II vs I | 0.68 [0.09–5.12] | 0.34 [0.04–2.86] | 0.26 [0.03–2.06] | 0.24 [0.02–2.34] | ||||
| III vs I | 2.47 [0.33–18.40] | 0.74 [0.08–6.99] | 1.15 [0.15–8.81] | 0.47 [0.04–5.57] | ||||
| SBR | 1.05 [0.51–2.16] | 0.89 | 1.94 [0.85–4.44] | 0.12 | 1.56 [0.53–4.58] | 0.417 | 3.2 [0.9–11.29] | 0.071 |
| 2 vs 1 | ||||||||
| 3 vs 1 | ||||||||
| pAJCC | < 0.001 | Not includeda | < 0.001 | Not includeda | ||||
| I vs 0 | 1.99 [0.77–5.15] | 1.63 [0.44–6.11] | ||||||
| II vs 0 | 3.59 [1.52–8.48] | 3.57 [1.22–10.46] | ||||||
| III vs 0 | 21.49 [8.82–52.37] | 16.97 [5.50–52.35] | ||||||
| pCR Yes vs No | 0.25 [0.12–0.54] | < 0.001 | 0.25 [0.11–0.59] | 0.0014 | 0.25 [0.10–0.66] | 0.005 | 0.21 [0.07–0.65] | 0.007 |
| HER2: low vs 0 | 1.84 [1.01–3.36] | 0.047 | 1.42 [0.7–2.88] | 0.335 | 2.3 [1.07–4.95] | 0.032 | 1.28 [0.47–3.49] | 0.628 |
RFS relapse-free survival, HR hazard ratio, CI confidence interval, OS overall survival, AJCC American Joint Committee on Cancer, c clinical, p pathological, SBR Scarff Bloom Richardson grade, pCR pathological complete response
aNot included: variables not included in multivariate models (pAJCC correlated with pCR)